UNITED NATIONS, Sep 18 2026 (IPS) - When a child is diagnosed with cancer, their chances of survival should not depend on where they live, yet according to the WHO, more than 80 percent of children with cancer in high-income countries are cured, compared with fewer than 30 percent in many low- and middle-income countries (LMICs).

The key gap lies in access to available medicines. In East Africa, hospitals report frequent stockouts of essential chemotherapy agents, with shortages affecting 32–49 percent of critical medicines such as methotrexate and etoposide. Survival therefore depends less on the discovery of new therapies and more on whether children are able to access and complete uninterrupted treatment.

“No child should be denied a chance of survival because the medicines they need are unavailable, unaffordable, or out of reach,” affirmed Dr Carlos Rodriguez-Galindo, Executive Vice President of St. Jude Children’s Research Hospital.

In efforts to combat this issue and in honor of Childhood Cancer Awareness Month, the World Health Organization (WHO) and its collaborators at the Global Platform for Access to Childhood Cancer Medicines published a new strategy report with a roadmap to strengthen the global market and improve the circulation of childhood cancer medicines in many LMICs.

Each year, an estimated 400,000 children develop cancer. Unlike many adult cancers, childhood cancer is generally not preventable. As a result, the most effective strategy for improving outcomes is to ensure that children receive a prompt and accurate diagnosis, followed by effective, evidence-based treatment and tailored supportive care.

The report highlighted many key barriers LMICs face when implementing this strategy. First, the supply of essential childhood cancer medicines is unreliable and depends on a small number of manufacturers, especially for medicines that meet international quality standards.

Secondly, LMICs often buy small amounts of cancer medicines, making supply less reliable and prices higher due to perceived low demand. Limited government funding and poor planning can also lead to shortages. Cancer medicines may take years to become available in LMICs because of slow approval processes. There is little investment in medicines designed specifically for children, especially for low-resource settings. This is partly because childhood cancer affects fewer people, making it a smaller market for companies.

“Persistent market challenges continue to affect access for children, and it is critical that we continue to work together to enhance the reliability and affordability of childhood cancer medicines,” said Dr. Kennedy Lishimpi, Permanent Secretary for Technical Services, Ministry of Health, Zambia.

Most types of childhood cancer can be cured with widely available generic medicines and other forms of treatment, including surgery and radiotherapy. Yet children in LMICs often face significant barriers to accessing these lifesaving interventions. Lower survival rates are driven by delays in diagnosis, difficulties obtaining an accurate diagnosis, limited access to appropriate therapy, treatment abandonment, death from treatment-related toxicity, and avoidable relapse.

Improving access to childhood cancer care, including essential medicines and technologies, has the potential to improve survival across all income settings.

The report also mentions how cost of treatment was another big barrier to care. In some cases, More than 70 percent of children being treated for leukaemia stop or do not complete their cancer treatment due to financial reasons.

The Global Platform prioritized a set of ten interventions in the report that will be implemented over 2026-2030. These included working more closely with medicine companies, increasing the number of reliable suppliers, speeding up medicine approval, improving planning and purchasing, and strengthening access to affordable, quality-assured childhood cancer medicines. The interventions also focused on supporting research, improving price information, including these medicines in national health coverage, and encouraging the development of new treatments.

“Rather than focusing only on individual products or prices, market shaping interventions aim to strengthen overall market health by improving the conditions required for sustainable access,” the report states.

In practice, this could look like integrating childhood cancer medications into national health benefit packages. For example, in 2024, Nepal declared free treatment for children with cancer at public health facilities.

“Where the price is more friendly, there are plenty of suppliers; that’s sort of the goal we’re trying to reach,” said Rongrong Liu, program manager from St. Jude’s global operations.

Additionally, the report also mentions that voluntary licensing could play an important role in improving access to new childhood cancer medicines in LMICs by allowing other quality-assured manufacturers to produce medicines that are still protected by patents. This could increase the number of suppliers, improve competition, lower prices, and help medicines reach LMICs sooner, reducing delays caused by high costs or dependence on a single manufacturer. The Global Platform plans to work with companies that own these medicines to negotiate licensing agreements for priority medicines. These agreements would allow selected manufacturers to produce and supply the medicines in LMICs under agreed conditions.

“At the beginning, we have focused only on clinical forecast, but in reality there are a lot of logistical parameters that we need to consider,” said Alessio Mola, pharmacist at WHO, emphasizing the importance of the proposed market strategies.

The newly launched roadmap provides good guidance on strengthening child cancer medicine markets and supply systems and is an essential step toward closing the survival gap and ensuring that where a child is born does not determine whether they survive cancer.

IPS UN Bureau Report